Showing results (781-790 of 1,839) with videos related to

Sort By:
Pageof 184
ESMO Open|November 28, 2025
Long-term outcome data for patients with hormone receptor-positive early breast cancer participating in the WSG PlanB trial after preselection by gene expression analysis: 10-year survival results from the WSG PlanB registryU Nitz, M Graeser, O Gluz, et al.
ESMO Open|November 21, 2025
Impact of the Lung Immune Prognostic Index in non-small-cell lung cancer patients with PD-L1-low/negative tumors receiving chemoimmunotherapy: a real-world multicenter retrospective studyA Yoshimura, T Takeda, K Tanimura, et al.
ESMO Open|November 21, 2025
Bevacizumab plus chemotherapy versus chemotherapy in untreated advanced non-squamous non-small-cell lung cancer patients with brain metastases (BAP BRAIN): an open-label, randomized, multicenter, phase III studyM Li, Y Pan, G Jiang, et al.
ESMO Open|November 20, 2025
Precision medicine strategy in pancreatic ductal adenocarcinomaA Tarabay, L Swales, C Smolenschi, et al.
ESMO Open|December 3, 2025
Streptozotocin plus 5-fluorouracil followed by everolimus or the reverse sequence in patients with advanced pancreatic neuroendocrine tumors (SEQTOR-GETNE phase III study): a randomized clinical trialJ Capdevila, S Tafuto, M Krogh, et al.
ESMO Open|November 30, 2025
Promoting equitable access to financial services to end financial discrimination against cancer survivors in Europe: scientific and ethical reasonsF André, D Soldato, I Vaz-Luis, et al.
ESMO Open|January 11, 2025
Nivolumab combination therapies in patients with advanced gastric and gastroesophageal junction cancer: the phase II FRACTION gastric cancer studyG Ku, G M Haag, H Park, et al.
ESMO Open|January 18, 2025
HER2DX in HER2-positive inflammatory breast cancer: correlative insights and comparative analysis with noninflammatory breast cancersF Lynce, O Martínez-Sáez, B Walbaum, et al.
ESMO Open|January 18, 2025
Molecular characterization of HER2-negative breast cancers reveals a distinct patient subgroup with 17q12 deletion and heterozygous loss of ERBB2X Qiu, P Tarantino, R Li, et al.
ESMO Open|February 5, 2025
Liver metastases do not predict resistance to the addition of atezolizumab to first-line FOLFOXIRI plus bevacizumab in proficient MMR metastatic colorectal cancer: a secondary analysis of the AtezoTRIBE studyC Antoniotti, M Carullo, D Rossini, et al.
Pageof 184